The new cloud-based data analytics platform is designed to reduce the complexity of deploying an antibiotic for complicated abdominal infections.
Shyft Analytics, which was acquired recently by Medidata Solutions and has created what they claim is the only intelligent platform for life sciences, has announced they were selected by Tetraphase Pharmaceuticals to assist them in their upcoming commercial launch of an antibiotic designed to address drug-resistant bugs in complicated abdominal infections. The launch of the drug, called eravacycline, is subject to regulatory approval.
Shyft’s platform is cloud-based and scalable and will give Tetraphase the tools it needs to gain commercial insights, market intelligence, and deep analytics, all of which will contribute to a successful drug launch.
“This is a pivotal time for Tetraphase, as we prepare to launch our first commercial product pending approval by the FDA. Ensuring we have the insights and analytics necessary to have a successful launch is critical,” said Larry Edwards, Chief Operating Officer at Tetraphase. “Shyft’s right-sized and scalable approach, combined with their deep expertise in helping specialty pharma brands successfully and quickly derive insights, will help us better address physician and patient needs, meet commercial milestones, and ensure we can scale to surpass our launch goals.”
Eravacycline, pending a final decision by the US Food and Drug Administration, plans to become commercially available later this year. Tetraphase will use Shyft’s Life Sciences platform to integrate their multiple data sources and create a comprehensive view of both clinical and commercial info, which will provide insights into both patient and payer needs.
“Addressing the increase in antibiotic resistance relies on effective novel therapies like Tetraphase’s eravacycline,” said Zack King, EVP Medidata, President of Shyft. “A product’s success in this therapeutic area requires a thorough understanding of the market, patients, and unique differentiators. We’re honored to partner with the Tetraphase team on an innovative approach to data analytics to ensure that new and life-changing therapies have the opportunity to thrive in an ever-changing, complex market. This is core to Shyft’s mission.”